An update from InhaleRx Limited ( (AU:IRX) ) is now available.
InhaleRx Limited held a General Meeting where a sole resolution was voted on, and the company expressed gratitude to its shareholders for their support. The company announced an upcoming Town Hall webinar led by the CEO and Medical Advisor to update on recent developments and clinical progress, highlighting its commitment to advancing its position in the healthcare industry.
More about InhaleRx Limited
InhaleRx Limited is an Australian healthcare company focused on developing innovative inhaled drug-device products targeting unmet medical needs in the pain management and mental health sectors. The company aims to achieve U.S. FDA approval through efficient regulatory pathways and is investigating treatments for Breakthrough Cancer Pain and Panic Disorder, which currently have limited effective options.
YTD Price Performance: -32.50%
Average Trading Volume: 114,607
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$5.76M
Learn more about IRX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com